Efficacy and safety of deferiprone for thalassemia: a systematic review and meta-analysis of randomized controlled trials

Gofarana Wilar, Cecep Suhandi, Ichiro Kawahata · 2025

Read Efficacy and safety of deferiprone for thalassemia: a systematic review and meta-analysis of randomized controlled trials by Gofarana Wilar, Cecep Suhandi, Ichiro Kawahata (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12821977.txt.

Description

People with thalassemia, an inherited blood disorder, take in extra iron from repeated transfusions, and that iron can damage the heart. Gofarana Wilar and two co-authors pooled the trial evidence in 2025 on deferiprone, a pill that pulls iron from the body. They gathered twenty-three randomized trials with about one thousand patients.

The pooled results showed better heart pumping scores on the drug, and more iron leaving in urine. Blood and liver iron measures did not shift clearly. Side effects were more common on the drug, though deaths were not. The authors rate the proof as moderate for heart gains and call for stronger trials to settle the best dosing plans.

Catalog record

CREATORGofarana Wilar, Cecep Suhandi, Ichiro Kawahata
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE44 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12821977

Browse the full library · About the Tower of Babel